📊 KYTX Key Takeaways
Is Kyverna Therapeutics, Inc. (KYTX) a Good Investment?
Kyverna Therapeutics is a pre-revenue biotech company with unsustainable financials, burning $153.7M annually in operating cash while generating no revenue, resulting in a ~12-month cash runway at current burn rates. While the balance sheet provides near-term cushion with $124.1M cash and minimal debt, deteriorating net losses (-$161.3M) and negative profitability metrics indicate the company requires near-term clinical/revenue breakthroughs or significant capital raises to survive.
Kyverna is a pre-revenue biotech with deeply negative profitability and rising operating losses, leading to substantial cash burn. While liquidity is strong with no debt and a high current ratio, the current cash balance appears insufficient against the burn rate, implying likely future financing needs. Absent revenue visibility or clear near-term inflection in operating efficiency, fundamentals skew unfavorable.
Why Buy Kyverna Therapeutics, Inc. Stock? KYTX Key Strengths
- Strong equity base of $232.3M with minimal debt leverage (Debt/Equity 0.00x)
- Substantial cash position of $124.1M providing near-term funding buffer
- Excellent liquidity position (7.75x current ratio) reducing insolvency risk in short term
- Active insider engagement with 7 Form 4 filings indicating management involvement
- Strong liquidity with a 7.75x current ratio
- Zero debt and minimal interest burden
- Low capital intensity (negligible capex) offers flexibility
KYTX Stock Risks: Kyverna Therapeutics, Inc. Investment Risks
- Pre-revenue company with zero revenue generation despite massive operating losses
- Severe cash burn of $153.7M annually with approximately 12-month cash runway remaining
- Deteriorating profitability trends with net loss down 26.5% YoY and EPS declining 9.3% YoY
- Unsustainable negative returns (ROE -69.4%, ROA -54.9%) with no path to profitability evident
- Likely requires additional capital raise or near-term clinical/regulatory milestone to avoid liquidity crisis
- Minimal capital expenditures ($5K) may indicate limited R&D investment or development delays
- No revenue with persistent, widening operating and net losses
- High operating cash burn (-$153.7M) implying short runway without new capital
- Negative ROE/ROA indicate poor capital efficiency
Key Metrics to Watch
- Cash burn rate trend and monthly cash consumption rate relative to remaining cash reserves
- Clinical trial milestones, regulatory approvals, and path to first revenue-generating product
- Capital raise announcements and financing arrangements extending runway beyond 12 months
- Operating expense trends and cost reduction initiatives affecting cash burn deceleration
- Quarterly operating cash burn (CFO)
- Cash & equivalents and runway duration
Kyverna Therapeutics, Inc. (KYTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.75x current ratio provides a solid financial cushion.
KYTX Profit Margin, ROE & Profitability Analysis
KYTX vs Healthcare Sector: How Kyverna Therapeutics, Inc. Compares
How Kyverna Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kyverna Therapeutics, Inc. Stock Overvalued? KYTX Valuation Analysis 2026
Based on fundamental analysis, Kyverna Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kyverna Therapeutics, Inc. Balance Sheet: KYTX Debt, Cash & Liquidity
KYTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kyverna Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.33 indicates the company is currently unprofitable.
KYTX Revenue Growth, EPS Growth & YoY Performance
Kyverna Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
KYTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kyverna Therapeutics, Inc. (CIK: 0001994702)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KYTX
What is the AI rating for KYTX?
Kyverna Therapeutics, Inc. (KYTX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KYTX's key strengths?
Claude: Strong equity base of $232.3M with minimal debt leverage (Debt/Equity 0.00x). Substantial cash position of $124.1M providing near-term funding buffer. ChatGPT: Strong liquidity with a 7.75x current ratio. Zero debt and minimal interest burden.
What are the risks of investing in KYTX?
Claude: Pre-revenue company with zero revenue generation despite massive operating losses. Severe cash burn of $153.7M annually with approximately 12-month cash runway remaining. ChatGPT: No revenue with persistent, widening operating and net losses. High operating cash burn (-$153.7M) implying short runway without new capital.
What is KYTX's revenue and growth?
Kyverna Therapeutics, Inc. reported revenue of N/A.
Does KYTX pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
Where can I find KYTX SEC filings?
Official SEC filings for Kyverna Therapeutics, Inc. (CIK: 0001994702) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KYTX's EPS?
Kyverna Therapeutics, Inc. has a diluted EPS of $-3.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KYTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kyverna Therapeutics, Inc. has a SELL rating with 74% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KYTX stock overvalued or undervalued?
Valuation metrics for KYTX: ROE of -69.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KYTX stock in 2026?
Our dual AI analysis gives Kyverna Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KYTX's free cash flow?
Kyverna Therapeutics, Inc.'s operating cash flow is $-153.7M, with capital expenditures of $5.0K.
How does KYTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -69.4% (avg: 15%), current ratio 7.75 (avg: 2).